Stay updated with breaking news from Davida Roth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tamibarotene plus azacitidine and venetoclax has received FDA fast track designation for newly diagnosed, unfit, RARA-overexpressed AML.
Syros Pharmaceuticals , a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food...
Tamibarotene is an oral selective retinoic acid receptor alpha (RARα) agonist. The FDA has granted Fast Track designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed AML with RARA overexpression.
The addition of the oral, selective RARα agonist tamibarotene to venetoclax and azacitidine produced higher responses rates compared with venetoclax and azacitidine alone in response-evaluable patients with newly diagnosed, RARA-overexpressed acute myeloid leukemia.
-- New data support further evaluation of SY-5609 for PDAC and HR+ breast cancer and demonstrate significant potential for SY-5609 in a wide range of tumor types and combinations -- -- Consistent... | May 25, 2023